MarketPulse
A

$ACLX

7 articles found
5 positive
2 negative
0 neutral
BenzingaBenzinga··Vandana Singh

Gilead Bolsters Inflammation Arsenal With $1.675B Ouro Medicines Deal

Gilead acquires Ouro Medicines for $1.675B upfront, targeting inflammation pipeline expansion. Galapagos NV partners to co-develop lead asset OM336.
GILDACLXGLPGacquisitionorphan drug designation
The Motley FoolThe Motley Fool··Jonathan Ponciano

Cormorant's $64M Arcellx Exit Preceded 77% Gilead Takeover Surge

Cormorant Asset Management exited its $63.63M Arcellx stake in Q4, missing an 80% year-to-date rally capped by Gilead Sciences' $7.8B acquisition announcement.
GILDACLXfund exitoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Halper Sadeh Llc

Investor Rights Firm Probes Three Companies Over Acquisition Deal Fairness

Halper Sadeh LLC investigates $ACLX, $VRE, $EHAB for potential shareholder fairness violations in proposed acquisitions.
ACLXEHABVREshareholder rightsacquisition
BenzingaBenzinga··Vandana Singh

Gilead to Acquire Oncology-Focused Arcellx in $7.8B Cash Deal

Gilead acquires oncology firm Arcellx for $7.8 billion in cash, adding CAR T-cell cancer therapy to its pipeline. Deal expected to close Q4 2024.
GILDACLXacquisitionM&A
GlobeNewswire Inc.GlobeNewswire Inc.··Halper Sadeh Llc

Law Firm Opens Inquiries Into Three M&A Deals Over Shareholder Value Concerns

Law firm Halper Sadeh investigates three M&A deals—Arcellx-Gilead, Enhabit-Kinderhook, and Veris Residential transactions—questioning whether shareholders receive adequate consideration and fair pricing.
ACLXEHABVREfair valuesecurities law violations
Investing.comInvesting.com··Timothy Fries

Gilead to Acquire Arcellx for $7.8B, Expanding CAR-T Therapy Portfolio

Gilead acquires Arcellx for $7.8B to expand CAR-T therapy portfolio, strengthening oncology pipeline and cell therapy capabilities.
GILDACLXacquisitionFDA approval
BenzingaBenzinga··Vandana Singh

Gilead to Acquire Arcellx for $7.8B to Expand CAR-T Oncology Portfolio

Gilead acquires Arcellx for $7.8B to gain CAR-T therapy anito-cel for multiple myeloma, with FDA approval expected by late 2026.
GILDACLXacquisitionFDA approval